Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Nephure™, and the Reduction of Dietary Oxalate, in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03661216
Recruitment Status : Completed
First Posted : September 7, 2018
Last Update Posted : September 19, 2018
Sponsor:
Information provided by (Responsible Party):
Donald Burkindine, D.O., QPS-Qualitix

Brief Summary:
The purpose of this double-blind study is to determine the effect of reducing oxalates in the diet of healthy volunteers by using Nephure, an oxalate-reducing enzyme, as compared to placebo.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: Nephure Oxalate-reducing Enzyme Other: Placebo Not Applicable

Detailed Description:
This study aims at evaluating the effect from Nephure in reducing dietary oxalate in healthy volunteers on a controlled diet as compared to placebo. Subjects are on a normal diet with controlled oxalate (750mg/day) and calcium (550mg/day) levels for 8 consecutive days. The study is a cross-over design with two four-day treatment periods. The study intends to determine level of reduction in urinary oxalate output as a measure of the effect of Nephure on dietary oxalate when ingested with a meal.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Double-blind, randomized, placebo-controlled, cross-over study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double (participant and investigator) and outcomes assessor
Primary Purpose: Other
Official Title: A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study With Nephure™, an Orally Administered Oxalate Reducing Enzyme
Actual Study Start Date : July 11, 2018
Actual Primary Completion Date : August 5, 2018
Actual Study Completion Date : August 5, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
3g of non-GMO maltodextrin
Other: Placebo
3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.

Active Comparator: Nephure
3g of Nephure
Dietary Supplement: Nephure Oxalate-reducing Enzyme
3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.




Primary Outcome Measures :
  1. Within-Subject Urinary Oxalate Excretion [ Time Frame: 8 days ]
    Milligram of oxalate per 24 hours is determined on dosing days. Within-subject difference in 24 hours urinary oxalate excretion between placebo and Nephure is determined.

  2. Between Groups Urinary Oxalate Excretion [ Time Frame: 8 days ]
    Milligram of oxalate per 24 hours is determined on dosing days. Mean difference in 24 hours urinary oxalate excretion between placebo and Nephure groups is determined.


Secondary Outcome Measures :
  1. Urinary Oxalate Excretion Compared to Baseline [ Time Frame: 8 days ]
    Difference in 24 hours urinary oxalate excretion between dosing days and the baseline day immediately preceding is determined.

  2. Adverse Events [ Time Frame: 8 days ]
    Number of participants with adverse events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject has granted written informed consent.
  2. Subject must be a male or non-pregnant female, at least 18 to 55 years of age at the time of Screening, and non-smoker for at least 3 months at the time of screening and throughout study.
  3. Subject has a BMI of 18.5 - 29.9 kg/m2 at the time of Screening.
  4. Subject has an estimated glomerular filtration rate (eGFR) of >90 mL/min/1.73 m2 at the time of Screening (GFR is calculated using the NIDDK provided equation at the following web address: www.niddk.nih.gov/health-information/communication-programs/nkdep/laboratory-evaluation/glomerular-filtration-rate-calculators/ckd-epi-adults-conventional-units.)
  5. Subject has a urinary oxalate <40.5mg/24 hours at the time of Screening .
  6. Subject has a urinary uric acid <750mg/24hour at the time of Screening1.
  7. Subject is in good health as determined by complete physical examination, medical history, vital signs, and laboratory tests.
  8. Subject is able to understand the study and be able to comply to the requirements and restrictions, including agreeing to complete the 24-hour urine collections, and has the ability to report their symptoms.
  9. Subject is able to comply with all dietary expectations and fluid intake at the discretion of the Principal Investigator (PI).
  10. Female subjects must agree to use an acceptable form of birth control from screening through the duration of the study (unless otherwise stated). See section 5.1.1.

Exclusion Criteria:

  1. Subject has a history or presence of clinically significant cardiovascular, pulmonary, respiratory, digestive, hepatic, renal, hematological, gastrointestinal (e.g., active bowel disease, known gallstones, GERD, etc.), endocrine, metabolic, immunological, infectious, dermatologic, neurological, psychological, or psychiatric disease or gastrointestinal surgeries (e.g., bowel resection, gastric bypass, cholecystectomy within the 6 months prior to screening, etc.), in the opinion of the Principal Investigator.
  2. Subject has received a positive result for urine drug screen at the screening visit or on Day -3, or has a history of positive test result(s) for human immunodeficiency virus (HIV) antibody, Hepatitis B surface antigen or Hepatitis C antibody.
  3. Subject has a history of or a current clinically significant medical condition, allergy, food sensitivity (e.g. maltodextrin) or surgical intervention that might significantly compromise the safety of the subject, interfere with study assessments, or impact the validity of the study results, in the opinion of the Principal Investigator.
  4. Subject is taking a medication that would indicate significant anxiety, depression, serious or unstable illness, or lack of good general health, that could interfere with the subject's ability to adhere to study instructions, or complete the study, in the opinion of the Principal Investigator and with approval of the Sponsor.
  5. Subject is unable or unwilling to discontinue use of dietary supplements (vitamins, minerals, and/or supplements) throughout the duration of the study or has used these products within 7 days prior to screening.
  6. Subject has continuously used (not including intermittent or rare PRN use) prescription or over the counter: proton pump inhibitors within 12 weeks of screening; or H2 blockers within 6 weeks of screening; or antacids within 2 weeks of screening.
  7. Subject is currently using medication that could affect oxalate handling such as cholestyramine, any carbonic anhydrase inhibitor, any steroid, any diuretic, any immunosuppressant drug, or has received chemotherapy or systemic immunosuppressive drugs within 6 mos. of their screening visit.
  8. Subject has had a clinically significant surgical procedure within 3 mos. prior to the Screening visit or planned surgical procedure during the study conduct.
  9. Subject has received an investigational product, device, or therapy within 30 days prior to screening.
  10. Subject has been on a self-restricted, controlled, or special therapeutic diet, or has had substantial changes in eating or bowel habits, or have had new GI complaints, within 30 days of their screening visit.
  11. Subject has been on systemic antibiotic therapy within 6 weeks prior to the screening visit or plans antibiotic therapy during the study conduct.
  12. Subject has a history of allergy or hypersensitivity to the study products, its excipients or any comparable products or excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03661216


Locations
Layout table for location information
United States, Missouri
QPS Bio-Kinetic Clinical Applications, LLC
Springfield, Missouri, United States, 65802
Sponsors and Collaborators
Captozyme, Inc.
Publications:
Layout table for additonal information
Responsible Party: Donald Burkindine, D.O., Principal Investigator, QPS-Qualitix
ClinicalTrials.gov Identifier: NCT03661216    
Other Study ID Numbers: 95318
First Posted: September 7, 2018    Key Record Dates
Last Update Posted: September 19, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No